Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blood test can accurately diagnose heart failure in emergency patients

11.04.2005


Measuring protein level provides accurate assessment for patients with shortness of breath

A new blood test that measures a particular marker of cardiac distress can markedly improve the ability to diagnose or exclude congestive heart failure in patients with shortness of breath who come to hospital emergency departments. The report from researchers at Massachusetts General Hospital (MGH) finds that measuring levels of a protein called NT-proBNP was significantly better at identifying heart failure than was standard clinical evaluation. The report will appear in the April 15 issue of the American Journal of Cardiology and has been released online prior to print publication.

"We found that testing with the NT-proBNP assay was an extremely accurate way to identify or exclude heart failure in patients with shortness of breath," says James Januzzi Jr., MD, of the MGH Cardiology Division, the paper’s lead author. "Importantly, we also found that the very best results came from combining the results of this very sensitive and specific blood test with the logic and wisdom of a good emergency physician, which gave the optimal balance between biologic data and clinical judgement."



Congestive heart failure, which occurs when an impaired heart muscle cannot pump blood efficiently, is a growing health problem and major cause of cardiac death. The diagnosis of heart failure may be difficult to make because its typical symptoms can overlap with those of other conditions. Missing a heart failure diagnosis can put patients at high risk of serious problems, including death, but overdiagnosis may lead patients to receive unnecessary treatment.

"To date, the way physicians have traditionally evaluated potential heart failure patients has been rather random, with some receiving a physical examination and medical history while others also get expensive and time-consuming procedures," Januzzi says. "Having a widely-available, accurate, and cost-effective diagnostic method would be of extraordinary value."

Proteins called natriuretic peptides are produced when the cardiac muscle is under stress. The role of testing for these proteins in several forms of cardiovascular disease has been the subject of intense recent study. In 2002, the newest generation of natriuretic peptide assays became available, and soon thereafter the current investigation – called the PRIDE study – was launched to determine the usefulness of a test for NT-proBNP in evaluating emergency patients. At the time of its launch, the PRIDE study was the first prospective American trial of NT-proBNP and the largest such study to study the test in patients with shortness of breath.

About 600 patients who came to the MGH Emergency Department with shortness of breath were enrolled in the study. In addition to standard evaluation of symptoms, a blood sample was drawn for NT-proBNP measurement. After the emergency assessment was completed, the attending physicians were asked to estimate the likelihood that the patients’ symptoms were caused by heart failure, based on all available information except the NT-proBNP assay. For patients admitted to the hospital, the entire record of their stay was included in the study data. Sixty days after the original emergency visit, the researchers followed up with each patient, contacting them personally and reviewing their records to identify any subsequent clinical events. Participation in the study in no way changed the care or treatment the patients received.

To determine the diagnoses for this study, cardiologists not involved in the patients’ care reviewed all the participants’ relevant hospital records from the initial emergency visit through the 60-day follow up. In assigning the final diagnosis – either acute heart failure or some other cause for shortness of breath – these physicians also did not have access to the NT-proBNP results.

When they reviewed NT-proBNP levels, the researchers found that the protein’s concentrations were significantly higher in patients eventually diagnosed with heart failure and highest in those with most severe symptoms. For identifying heart failure in these emergency patients, the test alone was significantly more accurate than was the physicians’ original likelihood assessment, but a combination of NT-proBNP levels and physician judgement produced the most accurate method of diagnosis.

"We also identified specific NT-proBNP levels above which the diagnosis of heart failure is clear and below which the symptoms are definitely not cardiac-related," Januzzi says. "So we’ve shown that this test not only can confidently exclude the presence of congestive heart failure, which other studies have examined, but can confirm that diagnosis as well. NT-proBNP performed exceptionally well and confirms the value of the natriuretic peptide class of cardiac biomarkers as a whole. We believe NT-proBNP testing should now become a routine component of evaluation for patients with shortness of breath in emergency department settings." Januzzi is an assistant professor of Medicine at Harvard Medical School.

Co-authors of the study – all from the MGH – are Carlos Camargo, MD, PhD; Saif Anwaruddin, MD; Aaron Baggish, MD; Annabel Chen, MD; Daniel Krauser, MD; Roderick Tung, MD; Renee Cameron, MS; Tobias Nagurney, MD; Claudia Chae, MD, MPH; Donald Lloyd-Jones, MD, ScM; David Brown, MD; Stacy Foran-Melanson, MD, PhD; Patrick Sluss, MD, PhD; Elizabeth Lee-Lewandrowski, PhD, MPH; and Kent Lewandrowski, MD. The study was supported by a grant from Roche Diagnostics, which manufacturers the NT-proBNP assay studied.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Complete skin regeneration system of fish unraveled

24.04.2018 | Life Sciences

Scientists create innovative new 'green' concrete using graphene

24.04.2018 | Materials Sciences

BAM@Hannover Messe: innovative 3D printing method for space flight

24.04.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>